Dabrafenib (GSK2118436)

Dabrafenib(GSK2118436)は、B-Rafの強力なATP競争的阻害剤で、 B-Raf、 B-RafV600E 、c-Rafに作用する時、 IC50 がそれぞれ 3.2 nM、 0.8 nM 、 5.0 nMです。

価格 在庫  
USD 113 あり
USD 163 あり
USD 214 あり
USD 226 あり
USD 340 あり
USD 504 あり

Dabrafenib (GSK2118436) 化学構造
分子量: 519.56

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare Raf Inhibitors
    Raf製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dabrafenib(GSK2118436)は、B-Rafの強力なATP競争的阻害剤で、 B-Raf、 B-RafV600E 、c-Rafに作用する時、 IC50 がそれぞれ 3.2 nM、 0.8 nM 、 5.0 nMです。
ターゲット B-raf B-RafV600E c-Raf
IC50 3.2 nM 0.8 nM 5.0 nM [1]
In vitro試験 Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MoPtT4lv[XOnIFHzd4F6 M2fPRWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMhfGGpZ3XkJGIuWmGoIG[2NFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[mmxdHnufYxifGWmLV3FT{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDifUBCdHCqYWPjdoVmdiCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6wNFA4KM7:TR?= M2\MdlI1QTByNkez
SK-MEL-28 NWLKeVE5U2mwYYPlJGF{e2G7 MXGxJIg> M{O3eWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2= MkjhNlQ6ODB4N{O=
HepG2 M4fhSGtqdmG|ZTDBd5NigQ>? NHPvbmdKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1? NE\6bWgzPDlyME[3Ny=>
COLO205 NH7WN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrRTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch|ryP MU[yOFkxODZ5Mx?=
HepG2 MmfsSpVv[3Srb36gRZN{[Xl? MVu0OUBucW5? NIL0WndFVVOR M1HCc2lvcGmkaYTpc44hd2ZiQXzrOUBqdiCWR1[tZoV1[S2|dHnteYxifGWmIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOvYXSyJJBpd3OyaH;yfYxifGmxbjD0doVifGWmIH\vdkA1PSCvaX7zJJBzcW:{IITvJHRITi2kZYThJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkhd2S7c4PlfUBjdG:2IIPjZY5v\XJiYX7hcJl{cXNid3n0bEBKSzVyIH;mJFMvPyEQvF2= NHvzdYIzPDlyME[3Ny=>
HFF MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xNEDPxE1? MVq3NkBp NF3iVXlFVVOR MW\Jcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN M2fzd|I{QDR2MEO4
SK-MEL-28 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? MX[3NkBp NH;JVlRFVVOR NV7acWxpUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIGPLMW1GVC1{ODDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMESzJO69VQ>? MmPCNlM5PDRyM{i=
A375P-F11 NIf4cHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxNEDPxE1? MnjQO|IhcA>? MkXzSG1UVw>? MmfLTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=> Mn7RNlM5PDRyM{i=
MALME-3M NHTFOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrXO|NPOTBizszN MoHjO|IhcA>? NYHPRXdXTE2VTx?= M4m2R2lEPTB;MTDuUS=> NWrhWmlGOjN6NESwN|g>
UACC-62 NGXv[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOxZpUyOCEQvF2= NF;Sd4o4OiCq M3\U[2ROW09? MXnJR|UxRTFibl2= M2\0WlI{QDR2MEO4
C32TG NUnRdWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rXNVExKM7:TR?= MkSzO|IhcA>? M4LTbWROW09? M{PWZmlEPTB;MTDuUS=> NVHaZW5IOjN6NESwN|g>
SK-MEL-1 M4LNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PuclExKM7:TR?= M4PZW|czKGh? M2nK[mROW09? M{DhUGlEPTB;MjDuUS=> MWCyN|g1PDB|OB?=
M14 M3zXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSyd|IyOCEQvF2= NVnXOWI5PzJiaB?= MX\EUXNQ NVLJPY1TUUN3ME2yJI5O MYqyN|g1PDB|OB?=
SK-MEL-28 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? MkGyO|IhcA>? NHqxTmRFVVOR NHK1THZKSzVyPUOgcm0> MYmyN|g1PDB|OB?=
A375 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH6VIEyOCEQvF2= M3XKUFczKGh? NF:weGhFVVOR Mn:xTWM2OD12IH7N M1PPblI{QDR2MEO4
DU-4475 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ucVExKM7:TR?= MlywO|IhcA>? M4\QWWROW09? MWnJR|UxRTVibl2= MmTKNlM5PDRyM{i=
UACC-257 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXzcYQ{OTBizszN NGfQPHA4OiCq MVLEUXNQ M3G3ZWlEPTB;NjDuUS=> NFXN[HczOzh2NECzPC=>
Colo 205 NXvKS4hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;HTIRjOTBizszN NHXHV5g4OiCq NUG0ZW8{TE2VTx?= MoGwTWM2OD15IH7N NVPjOVZ2OjN6NESwN|g>
SK-MEL-3 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHBSG4yOCEQvF2= M4XOWVczKGh? NYL0Z29tTE2VTx?= MUPJR|UxRTdibl2= MYeyN|g1PDB|OB?=
SH-4 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxNEDPxE1? NWnPTmtUPzJiaB?= Mn3vSG1UVw>? M4jQVGlEPTB;ODDuUS=> NYXKW3RzOjN6NESwN|g>
A101D NFXrXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLYNVAh|ryP MmfTO|IhcA>? NVvSOIU{TE2VTx?= MlfTTWM2OD17IH7N NIPYbYYzOzh2NECzPC=>
ES-2 NH7NVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnLe3cyOCEQvF2= NIPtd5I4OiCq M3XaNmROW09? Mm\aTWM2OD13MzDuUS=> MkfXNlM5PDRyM{i=
HT-29 NFX1fpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QUWsyOCEQvF2= NVv3ZXU1PzJiaB?= NGn2So5FVVOR MVnJR|UxRTZ4IH7N NF\LWIozOzh2NECzPC=>
SW1417 NVryU3UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17iNFExKM7:TR?= MU[3NkBp MVLEUXNQ NWW1S4diUUN3ME2xOVghdk1? M1fpU|I{QDR2MEO4
SW872 NWm4OHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\WOHEyOCEQvF2= NV3jR|R4PzJiaB?= MmTMSG1UVw>? NVz6bFR6UUN3ME2zO|chdk1? MUGyN|g1PDB|OB?=
RKO M13F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\CO5UyOCEQvF2= NX7FTG5mPzJiaB?= MUnEUXNQ M2\USmlEPTB;Mj61NlIh|ryP MXGyN|g1PDB|OB?=
A673 NFTKN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXtOFgyOCEQvF2= M2jWTVczKGh? M4nZeGROW09? NWfVdJM5UUN3ME2xNEDPxE1? NI\q[2gzOzh2NECzPC=>
GCT M2m4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNEDPxE1? MmT4O|IhcA>? MU\EUXNQ NWnOZ5hMUUN3ME2xNEDPxE1? MYeyN|g1PDB|OB?=
WM-115 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLTV|lROTBizszN MXy3NkBp MXnEUXNQ MU\JR|UxRTVibl2= MkDINlM5PDRyM{i=
YUMAC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljYNVAh|ryP M2XheVczKGh? NVu5Z|BtTE2VTx?= NYP1bodQUUN3ME21JI5O NXX4V3M4OjN6NESwN|g>
OV-90 NVv4cZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfYNVAh|ryP NIL2VFU4OiCq NWftcodpTE2VTx?= MW\JR|UxRTJ7IH7N M1KzdFI{QDR2MEO4
NCI-H508 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1T|ExKM7:TR?= MUS3NkBp MlnPSG1UVw>? MlTuTWM2OD1zMDFOwG0> Ml:0NlM5PDRyM{i=
MDA-MB-231 NIDaZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\wb2hWOTBizszN NHvWWJg4OiCq MkLLSG1UVw>? MVfJR|UxRTFyIN88US=> M37te|I{QDR2MEO4
SW756 M3\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMNVAh|ryP MnrhO|IhcA>? M{PMUGROW09? NUf4PHVEUUN3ME2xNEDPxE1? M17jPFI{QDR2MEO4
SW-837 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70NVAh|ryP NVuyU5NGPzJiaB?= MWDEUXNQ M1;MNWlEPTB;MUCg{txO NWPYV2RROjN6NESwN|g>
UMUC-3 NF76eZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHWSotkOTBizszN MVK3NkBp MUXEUXNQ M{LH[GlEPTB;MUCg{txO NFHEV5IzOzh2NECzPC=>
LS-174T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXLNVAh|ryP NXf1PIp4PzJiaB?= MmLnSG1UVw>? MmXrTWM2OD1zMDFOwG0> NWfm[GVnOjN6NESwN|g>
A549 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe0WZU2OTBizszN MnPnO|IhcA>? M1fuXmROW09? M1LYWWlEPTB;MUCg{txO M3rkeVI{QDR2MEO4
SHP-77 NH\uOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVexNEDPxE1? MnvMO|IhcA>? M1zPfWROW09? MnHHTWM2OD1zMDFOwG0> M4\2fFI{QDR2MEO4
SW480 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHTTllnOTBizszN M2DpeVczKGh? M2W3bWROW09? MWjJR|UxRTFyIN88US=> MnHxNlM5PDRyM{i=
DLD-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxNEDPxE1? M4LxU|czKGh? M1LiXmROW09? Mm\VTWM2OD1zMDFOwG0> MX6yN|g1PDB|OB?=
HCT-116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGxNVAh|ryP M4CxSVczKGh? NELXRmpFVVOR M1H4SmlEPTB;MUCg{txO M{TBe|I{QDR2MEO4
NCI-H747 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrJZYxKOTBizszN M{TjXlczKGh? Mm\VSG1UVw>? MYnJR|UxRTFyIN88US=> MmDRNlM5PDRyM{i=
T-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCycJVVOTBizszN MmW1O|IhcA>? MlOzSG1UVw>? MUDJR|UxRTFyIN88US=> M2jVTFI{QDR2MEO4
NCI-H460 NYnGcWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLwNVAh|ryP NYTqNIdUPzJiaB?= NH\CSoZFVVOR Ml7ITWM2OD1zMDFOwG0> NFnpNWczOzh2NECzPC=>
Calu-6 NWrmTZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxNEDPxE1? NXjkUW9vPzJiaB?= MXPEUXNQ NGT5Z4pKSzVyPUGwJO69VQ>? MnnvNlM5PDRyM{i=
HCC-2998 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv2eWpuOTBizszN NWL3NlZjPzJiaB?= MWLEUXNQ NWDBNWNMUUN3ME2xNEDPxE1? NWP1SXptOjN6NESwN|g>
LS1034 M1LVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PmdVExKM7:TR?= NGnsOnI4OiCq Mor0SG1UVw>? NUP4Tm8zUUN3ME2xNEDPxE1? M2fFclI{QDR2MEO4
CHP-212 NGfhfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHkdG5zOTBizszN MYG3NkBp M3S5NmROW09? NIHYOmpKSzVyPUGwJO69VQ>? MY[yN|g1PDB|OB?=
SK-N-AS NELVe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHUNVAh|ryP MUe3NkBp MVTEUXNQ NGfaZWlKSzVyPUGwJO69VQ>? MUOyN|g1PDB|OB?=
BFTC-905 M1j4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlriNVAh|ryP M4DGd|czKGh? NYTBVY1iTE2VTx?= MX3JR|UxRTFyIN88US=> NYXTV3pjOjN6NESwN|g>
HuT78 M3WwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPFNVAh|ryP NYDCOlV{PzJiaB?= NGPh[2FFVVOR MXrJR|UxRTV{IH7N M1fZUVI{QDR2MEO4
RPMI-8226 M2jKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxNEDPxE1? NE\xeYY4OiCq NH7Ve4hFVVOR NUTNPYJKUUN3ME2yOlMhdk1? NX\kdG9WOjN6NESwN|g>
BC-3 NG[5dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfrdoZVOTBizszN NGjvdWw4OiCq NFTtUIxFVVOR NWGyTVNlUUN3ME2yO|chdk1? MX[yN|g1PDB|OB?=
ACHN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? NIDDNGM4OiCq MWHEUXNQ MYrJR|UxRTJ7NDDuUS=> NUjX[3Z5OjN6NESwN|g>
JRT3-T35 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHUPWoyOCEQvF2= NITwPW84OiCq MkHWSG1UVw>? MWXJR|UxRTJ7NTDuUS=> M2nlS|I{QDR2MEO4
SK-MES-1 NUX4dIhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYixNEDPxE1? MVm3NkBp M3HDb2ROW09? MVjJR|UxRTN{OTDuUS=> MV2yN|g1PDB|OB?=
CESS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPhUFkyOCEQvF2= M3y4dVczKGh? NH[0cXhFVVOR NXLIRXRoUUN3ME20PVchdk1? NF\uXpEzOzh2NECzPC=>
H4 M4TQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\TRo9{OTBizszN MYq3NkBp MnTaSG1UVw>? NIDofWdKSzVyPU[xPUBvVQ>? MX2yN|g1PDB|OB?=
BC-1 NFPBfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\1TVExKM7:TR?= MlzyO|IhcA>? MUPEUXNQ MVjJR|UxRTdyNDDuUS=> NWDsPWdTOjN6NESwN|g>
DB M4LnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2eHIyOCEQvF2= MYG3NkBp MWrEUXNQ MVzJR|UxRTh5MzDuUS=> NX7o[I9mOjN6NESwN|g>
RPMI-6666 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfxNVAh|ryP NVi5T29lPzJiaB?= MVfEUXNQ MV\JR|UxRTl{ODDuUS=> M1PZ[|I{QDR2MEO4
MC/CAR M4rNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzkNVAh|ryP NUPVdVl[PzJiaB?= M3j2T2ROW09? M2fhR2lEPTB;MT6wNFIh|ryP MX:yN|g1PDB|OB?=
SNU-1 NYTmV|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xNEDPxE1? M37MZlczKGh? NV30S|hWTE2VTx?= MlGzTWM2OD1zLkWwNUDPxE1? NVTOZ4I{OjN6NESwN|g>
CEM/C1 NGnRbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvhNVAh|ryP MVu3NkBp MmHnSG1UVw>? Mk\1TWM2OD1zLke3N{DPxE1? MYiyN|g1PDB|OB?=
GDM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNEDPxE1? NXzQTIZQPzJiaB?= NVvC[3I3TE2VTx?= NUjaXGlyUUN3ME2xMlk6PyEQvF2= NHzqXo4zOzh2NECzPC=>
HT-1080 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\mOY9xOTBizszN NFnuU3o4OiCq MX;EUXNQ NYnqc|VkUUN3ME2yMlAxPCEQvF2= NGHyO|IzOzh2NECzPC=>
HL-60 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHrNVAh|ryP MYG3NkBp M{i5fWROW09? Mo\6TWM2OD1{LkG3PEDPxE1? M37rSFI{QDR2MEO4
C3A MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNEDPxE1? MUS3NkBp NXHE[JY1TE2VTx?= NWrTcVg6UUN3ME21MlQyPCEQvF2= NH\lOJozOzh2NECzPC=>
MES-SA MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\zV|ExKM7:TR?= MWG3NkBp MnvsSG1UVw>? MUnJR|UxRTZwOUi5JO69VQ>? MYmyN|g1PDB|OB?=
22Rv1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmxeWhWOTBizszN MkP3O|IhcA>? NE\3PZJFVVOR NF7UUZlKSzVyPUGwJO69VQ>? NFPqR|kzOzh2NECzPC=>
647-V NV;KV|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C5elExKM7:TR?= M1TmdlczKGh? NYD5emU4TE2VTx?= M1fDVWlEPTB;MUCg{txO NHr5PZQzOzh2NECzPC=>
786-O M3\OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXIWZVKOTBizszN NYDCZodqPzJiaB?= Mm\FSG1UVw>? NX7BWmtTUUN3ME2xNEDPxE1? M4PkclI{QDR2MEO4
A172 NV;4WJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEDPxE1? M3;Qe|czKGh? MmPFSG1UVw>? M3z0NGlEPTB;MUCg{txO NHv5N2gzOzh2NECzPC=>
A204 NUPzZXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npcVExKM7:TR?= M3mzTFczKGh? M2X4fGROW09? MmK1TWM2OD1zMDFOwG0> NIK2eoczOzh2NECzPC=>
A427 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT3NVAh|ryP NF7LdW44OiCq NXK1c2NUTE2VTx?= NUm5cJA3UUN3ME2xNEDPxE1? MlPTNlM5PDRyM{i=
A431 NFWz[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNEDPxE1? MmiwO|IhcA>? M{jWWmROW09? NFzoSmRKSzVyPUGwJO69VQ>? NYXufIpOOjN6NESwN|g>
A2780 NVXmXllbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPPOWVEOTBizszN NH\4OVA4OiCq MWDEUXNQ MljmTWM2OD1zMDFOwG0> MnztNlM5PDRyM{i=
ARH-77 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f0NlExKM7:TR?= M4HxcVczKGh? M{LNfWROW09? MULJR|UxRTFyIN88US=> MmL3NlM5PDRyM{i=
Be(2)C NV[zeY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEDPxE1? M3XsR|czKGh? MnezSG1UVw>? M{fZc2lEPTB;MUCg{txO MUCyN|g1PDB|OB?=
BT-20 NE\GcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPVW3YyOCEQvF2= NHLpNIE4OiCq NF7rOXlFVVOR MmjhTWM2OD1zMDFOwG0> Ml3RNlM5PDRyM{i=
BxPc3 M{W5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u4UlExKM7:TR?= NEjtRnk4OiCq NHq5TpVFVVOR MmLoTWM2OD1zMDFOwG0> NHK5S24zOzh2NECzPC=>
C-4 I NIfGRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNEDPxE1? M{OwWVczKGh? NHPtdYZFVVOR MVfJR|UxRTFyIN88US=> MlK1NlM5PDRyM{i=
C33A M122Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Ht[FExKM7:TR?= NYrSXod7PzJiaB?= M{DFfWROW09? M{e2NmlEPTB;MUCg{txO NXj1[WdjOjN6NESwN|g>
CAL-27 NYPmTJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVywXXVtOTBizszN M3XPbVczKGh? MUDEUXNQ Mo\RTWM2OD1zMDFOwG0> Ml\RNlM5PDRyM{i=
CAL-62 M37J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z6WlExKM7:TR?= M{HEclczKGh? MWDEUXNQ MXrJR|UxRTFyIN88US=> MmPENlM5PDRyM{i=
Calu-3 NIPxRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvNVAh|ryP NXjDTVZ2PzJiaB?= NHvEVFVFVVOR NXu0WZBzUUN3ME2xNEDPxE1? Mlq0NlM5PDRyM{i=
CaOV3 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nGZ|ExKM7:TR?= M4njbFczKGh? MULEUXNQ MnHETWM2OD1zMDFOwG0> NWnLdZQyOjN6NESwN|g>
CGTHW1 NVfGXXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn1fYwyOCEQvF2= NFOyfpM4OiCq Ml\LSG1UVw>? NWPxTIRZUUN3ME2xNEDPxE1? NIDFd5EzOzh2NECzPC=>
CHL-1 MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq2RlQ1OTBizszN NIe2Z2I4OiCq NW\zcGFiTE2VTx?= MonUTWM2OD1zMDFOwG0> MoDBNlM5PDRyM{i=
Colo320DM NGjY[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNEDPxE1? MXO3NkBp M1XFdGROW09? MmfJTWM2OD1zMDFOwG0> NFSxN4ozOzh2NECzPC=>
Colo704 M33ZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SzZVExKM7:TR?= Mon1O|IhcA>? M3rB[2ROW09? NWW2S4hqUUN3ME2xNEDPxE1? M3q4[VI{QDR2MEO4
COR-L23 M2\Ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexNEDPxE1? M2PxRVczKGh? MoDrSG1UVw>? M3fnfmlEPTB;MUCg{txO MVOyN|g1PDB|OB?=
CRO-AP2 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WRVExKM7:TR?= MoOwO|IhcA>? NIPEcnhFVVOR NFXFPHBKSzVyPUGwJO69VQ>? NXrIUmtvOjN6NESwN|g>
Daudi NIPlZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHKVZEyOCEQvF2= M3;hb|czKGh? MlnqSG1UVw>? NF;2eHhKSzVyPUGwJO69VQ>? NWrqUGh6OjN6NESwN|g>
DOTC 24510 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? M13BdlczKGh? MlzUSG1UVw>? MoP2TWM2OD1zMDFOwG0> MX2yN|g1PDB|OB?=
DU-145 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCzOnI3OTBizszN NXexe3gxPzJiaB?= NY\CWXd3TE2VTx?= MWnJR|UxRTFyIN88US=> NETpR3IzOzh2NECzPC=>
EB-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnMd2VwOTBizszN MU[3NkBp NULSVHJyTE2VTx?= M{C3VmlEPTB;MUCg{txO NFHQfFAzOzh2NECzPC=>
EFM-19 NF3KSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNEDPxE1? M4PYXFczKGh? NU\IN4hYTE2VTx?= MmnrTWM2OD1zMDFOwG0> MXOyN|g1PDB|OB?=
EKVX MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2cJkyOCEQvF2= MXm3NkBp NYrmTIl4TE2VTx?= NGnmUYhKSzVyPUGwJO69VQ>? MnfNNlM5PDRyM{i=
FaDu MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qNVAh|ryP NVfx[YlxPzJiaB?= M4XQ[GROW09? M4TWSmlEPTB;MUCg{txO NFT1eWozOzh2NECzPC=>
G401 M2f4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXaNVAh|ryP NYPQNWw{PzJiaB?= M{HkNGROW09? Mm\3TWM2OD1zMDFOwG0> M4HPbFI{QDR2MEO4
HCC-70 NHToWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrze4hsOTBizszN NF;pT2o4OiCq MV7EUXNQ NUW3dZlEUUN3ME2xNEDPxE1? NWPjfY1GOjN6NESwN|g>
HCC-1954 M2\oUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLaNVAh|ryP MVm3NkBp MX3EUXNQ M3vQUGlEPTB;MUCg{txO MYSyN|g1PDB|OB?=
Hela MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3PHlTOTBizszN MWi3NkBp MVnEUXNQ NUWyOXRxUUN3ME2xNEDPxE1? M2XOVFI{QDR2MEO4
Hep3B M{CwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjbFkyOCEQvF2= M{LGSFczKGh? NFLJS5JFVVOR M{joN2lEPTB;MUCg{txO NEnOXHYzOzh2NECzPC=>
HMCB NUj1XGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNEDPxE1? MXS3NkBp NVnCVFRvTE2VTx?= MY\JR|UxRTFyIN88US=> NXP3TpVnOjN6NESwN|g>
HN5 M4fQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNEDPxE1? NHzoUII4OiCq Ml7FSG1UVw>? MXXJR|UxRTFyIN88US=> MVyyN|g1PDB|OB?=
HOS M4LlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNEDPxE1? MlrZO|IhcA>? NETZeY5FVVOR NYW1PIpLUUN3ME2xNEDPxE1? NX\iVHN{OjN6NESwN|g>
HPAF-II MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNEDPxE1? MYi3NkBp NIfU[lVFVVOR NFLmPGpKSzVyPUGwJO69VQ>? MV:yN|g1PDB|OB?=
Hs746.T NX3JNXZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlNVAh|ryP MVK3NkBp MnzFSG1UVw>? MVvJR|UxRTFyIN88US=> M4XQOFI{QDR2MEO4
HT NIXkfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTHfHh1OTBizszN MYq3NkBp NXz3NYs3TE2VTx?= MnHmTWM2OD1zMDFOwG0> NF\LeHgzOzh2NECzPC=>
HT-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3NVAh|ryP Ml\kO|IhcA>? NED0XZZFVVOR Ml;jTWM2OD1zMDFOwG0> NVO3XZpDOjN6NESwN|g>
HuNS-1 M4L2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlznNVAh|ryP MYK3NkBp Ml;3SG1UVw>? MkPuTWM2OD1zMDFOwG0> NEf4cnEzOzh2NECzPC=>
IGROV1 NITTZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT5TGwyOCEQvF2= M1jVb|czKGh? Ml[2SG1UVw>? Mnr2TWM2OD1zMDFOwG0> MoXmNlM5PDRyM{i=
J82 NGXPWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojDNVAh|ryP NHnmV4g4OiCq MV7EUXNQ M1qyR2lEPTB;MUCg{txO NFTKWIMzOzh2NECzPC=>
JM1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj1[JEyOCEQvF2= M3TTNFczKGh? M1jiUGROW09? MU\JR|UxRTFyIN88US=> NY\xSnI6OjN6NESwN|g>
Kato III NUHFboExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj5OnZrOTBizszN MmLQO|IhcA>? NXTrPHE{TE2VTx?= NXq5NoNpUUN3ME2xNEDPxE1? MkPSNlM5PDRyM{i=
KHOS-240S MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNEDPxE1? NU\vS3M{PzJiaB?= NHPkRXlFVVOR MUfJR|UxRTFyIN88US=> MX[yN|g1PDB|OB?=
KM-12 NUHYTFc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HIXFExKM7:TR?= M2jvclczKGh? NVnQ[FRQTE2VTx?= MUPJR|UxRTFyIN88US=> NWfSNpZIOjN6NESwN|g>
KPL-1 NHG1RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:yPVExKM7:TR?= NFTEXIs4OiCq M{HyWGROW09? MUfJR|UxRTFyIN88US=> MVKyN|g1PDB|OB?=
KYSE-30 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxNEDPxE1? MXG3NkBp NFiwNVVFVVOR NXPOcmxHUUN3ME2xNEDPxE1? NITZboMzOzh2NECzPC=>
LNCaP M2[wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqxNEDPxE1? M2HpdFczKGh? M2HkW2ROW09? MUjJR|UxRTFyIN88US=> NIW0cG4zOzh2NECzPC=>
MCF-7 NXG2ZlE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rsR|ExKM7:TR?= MXG3NkBp MornSG1UVw>? MoPHTWM2OD1zMDFOwG0> NHLFNngzOzh2NECzPC=>
MC-IXC NYq2NIs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KxUVExKM7:TR?= NWLOOlR4PzJiaB?= Mn3ISG1UVw>? NIrsZotKSzVyPUGwJO69VQ>? M2nvV|I{QDR2MEO4
MDA-MB-175 VII MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTUNVAh|ryP MoHvO|IhcA>? Mm\ZSG1UVw>? NGDYfFlKSzVyPUGwJO69VQ>? NHjlbGozOzh2NECzPC=>
MDA-MB-468 NGHhenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5c5EyOCEQvF2= NFjtSYM4OiCq NUDPdZdxTE2VTx?= MoPYTWM2OD1zMDFOwG0> MlrXNlM5PDRyM{i=
MiaPaCa M3rldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXmNVAh|ryP M{XnWFczKGh? NFLDXm9FVVOR M121[WlEPTB;MUCg{txO M3ezXFI{QDR2MEO4
Molt-4 M3z3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fXd|ExKM7:TR?= Mn3MO|IhcA>? NHO1dYpFVVOR MV3JR|UxRTFyIN88US=> M2C2[FI{QDR2MEO4
NCI-ADR/RES NHWwXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTPWGpSOTBizszN M{XqRlczKGh? MWXEUXNQ MWXJR|UxRTFyIN88US=> M{LvSFI{QDR2MEO4
NCI-H69 NUTRZ21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK1cnVFOTBizszN NEXlfWM4OiCq M2XCPWROW09? MmXWTWM2OD1zMDFOwG0> M3L6cFI{QDR2MEO4
NCI-H82 NVjaV|hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fXO|ExKM7:TR?= MXe3NkBp NWL6PFM3TE2VTx?= MnLwTWM2OD1zMDFOwG0> MVGyN|g1PDB|OB?=
NCI-N87 M1nqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTPVExKM7:TR?= M{S5VVczKGh? MYDEUXNQ NIKzOnhKSzVyPUGwJO69VQ>? NFzKbYszOzh2NECzPC=>
NCI-H146 M3HCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNEDPxE1? MVe3NkBp M4LBbmROW09? MmHDTWM2OD1zMDFOwG0> M2jBR|I{QDR2MEO4
NCI-H157 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\IfVExKM7:TR?= NUfzSoVlPzJiaB?= M4jJXWROW09? Mm\jTWM2OD1zMDFOwG0> MUSyN|g1PDB|OB?=
NCI-H187 M3nYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrNVAh|ryP M4DNVlczKGh? MUXEUXNQ NGHUdJFKSzVyPUGwJO69VQ>? MonkNlM5PDRyM{i=
NCI-H209 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n0UlExKM7:TR?= MUO3NkBp NV;5dZh[TE2VTx?= NX\U[pNzUUN3ME2xNEDPxE1? MnrhNlM5PDRyM{i=
NCI-H226 M{TibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO0WlUyOCEQvF2= MkLmO|IhcA>? MWrEUXNQ MUPJR|UxRTFyIN88US=> MYqyN|g1PDB|OB?=
NCI-H292 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxZo0yOCEQvF2= MlTqO|IhcA>? NVT6ZldXTE2VTx?= Mn7uTWM2OD1zMDFOwG0> M3izflI{QDR2MEO4
NCI-H322 M13EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3UVgyOCEQvF2= MlfqO|IhcA>? MX;EUXNQ NU\yVXB[UUN3ME2xNEDPxE1? MX:yN|g1PDB|OB?=
NCI-H358 M3vLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrHbnF[OTBizszN NYTwfVlHPzJiaB?= NXjvZXJjTE2VTx?= M1nZZ2lEPTB;MUCg{txO MVKyN|g1PDB|OB?=
NCI-H520 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNEDPxE1? M3vqOlczKGh? NWD6T5RrTE2VTx?= NYjU[ZRXUUN3ME2xNEDPxE1? Mne1NlM5PDRyM{i=
NCI-H526 NFiwS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNEDPxE1? NWDYRohsPzJiaB?= MojmSG1UVw>? M3zEcWlEPTB;MUCg{txO M2Xq[FI{QDR2MEO4
NCI-H630 NXXhRlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLqOlAyOCEQvF2= MnjNO|IhcA>? NX\GOJBETE2VTx?= NFPDWm9KSzVyPUGwJO69VQ>? NXfReFlNOjN6NESwN|g>
NCI-H661 M{[1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorWNVAh|ryP M1XjOlczKGh? Mo\SSG1UVw>? NX\I[phFUUN3ME2xNEDPxE1? NETGPGQzOzh2NECzPC=>
NCI-H716 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;Xc|ExKM7:TR?= MkjmO|IhcA>? M4jxUGROW09? MV7JR|UxRTFyIN88US=> M1TZW|I{QDR2MEO4
NCI-H1563 NHzQPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWixd2xuOTBizszN NY\FbpR6PzJiaB?= NWTaWFR2TE2VTx?= M2nPbGlEPTB;MUCg{txO NUj6NFJzOjN6NESwN|g>
NCI-H1792 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNEDPxE1? NIfKSFQ4OiCq MXjEUXNQ NWP5[W9YUUN3ME2xNEDPxE1? M3;zNVI{QDR2MEO4
NCI-H2030 NHnkdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvyNVAh|ryP MmHkO|IhcA>? M3nFcmROW09? Ml7tTWM2OD1zMDFOwG0> M4DB[FI{QDR2MEO4
NCI-H2052 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxNEDPxE1? NWTpNIJGPzJiaB?= M4jSU2ROW09? MonpTWM2OD1zMDFOwG0> MXKyN|g1PDB|OB?=
NCI-H2122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[3bHcyOCEQvF2= M2O0cVczKGh? M3PNUWROW09? Mln2TWM2OD1zMDFOwG0> NV3CNW5zOjN6NESwN|g>
NCI-H2228 NI\VdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X5VFExKM7:TR?= NGXDR3g4OiCq MkLHSG1UVw>? MnvnTWM2OD1zMDFOwG0> NXfTfVkxOjN6NESwN|g>
OE-19 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXUNVAh|ryP MUW3NkBp NYPJenRpTE2VTx?= NYPheWNKUUN3ME2xNEDPxE1? Mn7jNlM5PDRyM{i=
OE-21 NXr5UJF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;ndVYyOCEQvF2= MX:3NkBp MUnEUXNQ NIKwOWVKSzVyPUGwJO69VQ>? NFzYRmYzOzh2NECzPC=>
OE-33 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrTN4UyOCEQvF2= M17HPFczKGh? MmHISG1UVw>? NV:wS3M6UUN3ME2xNEDPxE1? MkPHNlM5PDRyM{i=
OVCAR-3 M2fLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jIblExKM7:TR?= NX;pdJVmPzJiaB?= M2fZUGROW09? MYLJR|UxRTFyIN88US=> MofONlM5PDRyM{i=
OVCAR-4 NHHJcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fvUFExKM7:TR?= NF;DN4M4OiCq MmrQSG1UVw>? MnLSTWM2OD1zMDFOwG0> MWOyN|g1PDB|OB?=
OVCAR-5 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i4clExKM7:TR?= MV[3NkBp M{DJTmROW09? NHK4VWFKSzVyPUGwJO69VQ>? MnXRNlM5PDRyM{i=
P3HR-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTiV|k4OTBizszN MUe3NkBp MX7EUXNQ MXnJR|UxRTFyIN88US=> NIjwUGMzOzh2NECzPC=>
PC-3 M2rl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNEDPxE1? MX:3NkBp M3Ptd2ROW09? NFH1e29KSzVyPUGwJO69VQ>? M4\VTVI{QDR2MEO4
Raji NF;xSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2UlExKM7:TR?= NWLmcJRKPzJiaB?= NXr4e28xTE2VTx?= M1T4RWlEPTB;MUCg{txO NGiyfnkzOzh2NECzPC=>
RD MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jhVlExKM7:TR?= NH7tV284OiCq M4LNW2ROW09? MV\JR|UxRTFyIN88US=> NEn1ToIzOzh2NECzPC=>
RD-ES MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmxNEDPxE1? M{jmPVczKGh? NYfncmxVTE2VTx?= NHzPfopKSzVyPUGwJO69VQ>? M1XWSFI{QDR2MEO4
RL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvWNVAh|ryP NXzkenFFPzJiaB?= MV;EUXNQ MXzJR|UxRTFyIN88US=> NHHxO4czOzh2NECzPC=>
SaOS2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4ZYZVOTBizszN M3T3ZVczKGh? MYDEUXNQ M2S3V2lEPTB;MUCg{txO NWHJNWllOjN6NESwN|g>
SCC-9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuwXGgyOCEQvF2= M13zOFczKGh? M{LzUGROW09? Mk\3TWM2OD1zMDFOwG0> NVnjWWx{OjN6NESwN|g>
SCC-12 NUDjSY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojkNVAh|ryP NYXuSYlbPzJiaB?= NX;sZ3NwTE2VTx?= MVnJR|UxRTFyIN88US=> NFXMN2ozOzh2NECzPC=>
SCC-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zVVExKM7:TR?= NIH2d3I4OiCq MkLlSG1UVw>? M4exXGlEPTB;MUCg{txO MXqyN|g1PDB|OB?=
SCC-15 M1TjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEe2syOCEQvF2= M1u1cFczKGh? NIXWWJZFVVOR NYfjTpFjUUN3ME2xNEDPxE1? MkS1NlM5PDRyM{i=
SCC-25 M2D2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml25NVAh|ryP NWnKOXc{PzJiaB?= NH7BXFFFVVOR NF\nXFRKSzVyPUGwJO69VQ>? NWrQb5RtOjN6NESwN|g>
SCLC-3 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\L[|BHOTBizszN Mnf4O|IhcA>? NWLDe2xHTE2VTx?= M4HGOGlEPTB;MUCg{txO MYqyN|g1PDB|OB?=
SF-268 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3js[|ExKM7:TR?= NHX6[nI4OiCq MkDWSG1UVw>? NIrjWoZKSzVyPUGwJO69VQ>? MkPkNlM5PDRyM{i=
SF-295 M3L4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\LNVAh|ryP M{CxR|czKGh? MULEUXNQ MnzZTWM2OD1zMDFOwG0> NUDWTllFOjN6NESwN|g>
SJRH30 NInpOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPSRpkyOCEQvF2= NH:zTFQ4OiCq MmTzSG1UVw>? M1PKRWlEPTB;MUCg{txO MUeyN|g1PDB|OB?=
SK-BR-3 M1\vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHONVAh|ryP MX[3NkBp NUTCV4l5TE2VTx?= NVHsWmduUUN3ME2xNEDPxE1? MXKyN|g1PDB|OB?=
SK-LMS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fE[lExKM7:TR?= NIm1fJk4OiCq NH3MOmxFVVOR MkeyTWM2OD1zMDFOwG0> NFrDcokzOzh2NECzPC=>
SK-N-DZ MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL5NVAh|ryP MUW3NkBp NX7uNWtUTE2VTx?= NF7Hb3BKSzVyPUGwJO69VQ>? NIL2coIzOzh2NECzPC=>
SK-N-F1 M1rFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETjbpQyOCEQvF2= NF:zbpI4OiCq Mm\2SG1UVw>? M1SxT2lEPTB;MUCg{txO NVqxXZo1OjN6NESwN|g>
SKOV-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LQ[FExKM7:TR?= NYLWOoR7PzJiaB?= NFXNT2FFVVOR NFjDV5dKSzVyPUGwJO69VQ>? NIPteY0zOzh2NECzPC=>
SK-UT-1 NHfMN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f1ZVExKM7:TR?= NWm0WGF5PzJiaB?= MUHEUXNQ NV3rUINsUUN3ME2xNEDPxE1? NUD1Z5VQOjN6NESwN|g>
SN12C M13TPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe3fGwyOCEQvF2= M3nBbFczKGh? NYryVWhxTE2VTx?= MULJR|UxRTFyIN88US=> M3Hjd|I{QDR2MEO4
SNB-19 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TZeFExKM7:TR?= MUm3NkBp MX;EUXNQ Ml;pTWM2OD1zMDFOwG0> MXyyN|g1PDB|OB?=
SNU-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:xeZIyOCEQvF2= M4XQU|czKGh? NFTYUlJFVVOR MWHJR|UxRTFyIN88US=> NHjTOpMzOzh2NECzPC=>
SNU-16 M1jGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO1NVAh|ryP MlzUO|IhcA>? M3PJRWROW09? NFXUTldKSzVyPUGwJO69VQ>? MV6yN|g1PDB|OB?=
SNU-398 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTNVAh|ryP M{nsS|czKGh? M1LNSGROW09? NWfQUm5wUUN3ME2xNEDPxE1? MUGyN|g1PDB|OB?=
SNU-449 NGixU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECwfZkyOCEQvF2= M2Hic|czKGh? MVHEUXNQ MVnJR|UxRTFyIN88US=> NEfWS48zOzh2NECzPC=>
SR NG\zN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVexNEDPxE1? NI\PR2I4OiCq MkfkSG1UVw>? MX3JR|UxRTFyIN88US=> NGfHTGczOzh2NECzPC=>
ST486 NWDmfYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpT|ExKM7:TR?= MYO3NkBp MWjEUXNQ NXi2fnZzUUN3ME2xNEDPxE1? NF\xUVIzOzh2NECzPC=>
SW579 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O3PFExKM7:TR?= NFHZeZU4OiCq NF3B[3hFVVOR NGPoOY5KSzVyPUGwJO69VQ>? NGj5OlczOzh2NECzPC=>
SW684 NVX4W5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDpNVAh|ryP M1vBR|czKGh? NXfNOZdDTE2VTx?= MV;JR|UxRTFyIN88US=> NYLsd|FsOjN6NESwN|g>
SW-780 M3PB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXxPYg6OTBizszN NGDaPJg4OiCq MnnTSG1UVw>? NX7Z[FFNUUN3ME2xNEDPxE1? NFzpO4ozOzh2NECzPC=>
SW900 NXXPRYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvFNVAh|ryP MVm3NkBp MYnEUXNQ NXPOVWc6UUN3ME2xNEDPxE1? NF;tOJczOzh2NECzPC=>
SW1088 NYDrVlJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X0UVExKM7:TR?= NYrBUXNVPzJiaB?= MXHEUXNQ M{S1NWlEPTB;MUCg{txO MoTnNlM5PDRyM{i=
SW1463 NVXaNm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXRc4MyOCEQvF2= NGnGemM4OiCq M2Lxe2ROW09? NHy5Z4xKSzVyPUGwJO69VQ>? Mlj0NlM5PDRyM{i=
SW1990 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDUUpAyOCEQvF2= M3vUXVczKGh? M{PwcmROW09? M3nOPGlEPTB;MUCg{txO NIn0eG4zOzh2NECzPC=>
T47D MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjFV|QyOCEQvF2= NYnyU5VHPzJiaB?= M1fQWWROW09? NFe0Tm5KSzVyPUGwJO69VQ>? NWLCc4dZOjN6NESwN|g>
TE381.T Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyyNVAh|ryP MnvDO|IhcA>? MXTEUXNQ Mof5TWM2OD1zMDFOwG0> M4OweVI{QDR2MEO4
TK-10 NVjnVXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX33TZBvOTBizszN NYfNPGYyPzJiaB?= M{PTW2ROW09? M3;3cWlEPTB;MUCg{txO MWmyN|g1PDB|OB?=
U2OS NGrTTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNEDPxE1? NXjKdY5xPzJiaB?= MoXlSG1UVw>? MmXwTWM2OD1zMDFOwG0> MXyyN|g1PDB|OB?=
U251 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD6RZdEOTBizszN Ml7LO|IhcA>? NH34TZFFVVOR MoX2TWM2OD1zMDFOwG0> MX6yN|g1PDB|OB?=
UACC-812 M1PHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfKTJQyOCEQvF2= NWXNeGdQPzJiaB?= NVjaem5uTE2VTx?= MWrJR|UxRTFyIN88US=> NWLUSGpQOjN6NESwN|g>
YAPC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj3NVAh|ryP NUjTXZR7PzJiaB?= M3LrbWROW09? MVvJR|UxRTFyIN88US=> MVeyN|g1PDB|OB?=
ZR-75-1 M2DmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XxbFExKM7:TR?= MWm3NkBp NIXXd|VFVVOR NHzQXIpKSzVyPUGwJO69VQ>? M2PDOVI{QDR2MEO4
A375 M2S2Z2Z2dmO2aX;uJIF{e2G7 NIDDeWIyNjJizszN MoDFOEBp MkfISG1UVw>? M4LEbmlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S MonYNlI{QDl2N{G=
YUSIT1 M2H6NWZ2dmO2aX;uJIF{e2G7 NVTwfXV4TE2VTx?= M3;NU5Jm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR|UxKD5iMD61JO69VQ>? M1HXWVIzOzh7NEex
MeWo NXj6elNPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLXSG1UVw>? M32zeWlEPTBiPTC5PFchdk1? Ml63NlYxOTh3MkS=
WiDr MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfEUXNQ M3[4TWlEPTBiPTC3OkBvVQ>? NYLTepFwOjZyMUi1NlQ>
Colo-205 NEW1dFRHfW6ldHnvckBie3OjeR?= M3PiN|Eh|ryP NYHT[mZHPCCm NH\Hc4VFVVOR MYHJcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU> NWXwWoFzOjV|OEGxOVI>
RBW-1 MV3GeY5kfGmxbjDhd5NigQ>? MVixJO69VQ>? NXnW[FIzTE2VTx?= NUH4TGt1Vm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w MkD0NlQ5QDV4OUC=
RBO-1 M3\BXWZ2dmO2aX;uJIF{e2G7 NWDJZWxVOSEQvF2= NGPUTVdFVVOR MlLmTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> MYmyOFg5PTZ7MB?=
RBO-2 NVW4SFNlTnWwY4Tpc44h[XO|YYm= M1HxUlEh|ryP M336NWROW09? MVjJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> Mn63NlQ5QDV4OUC=
RBOW NHnBelBHfW6ldHnvckBie3OjeR?= NHT1SpkyKM7:TR?= MUHEUXNQ MlrRTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NXj5N4tqOjR6OEW2PVA>
M257 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGntOG4yODBibl2= M1HIdVczKGh? NHraWZRFd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NVn3R3pXOjN|MUe0OFY>
LCP M1\rS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1NVAxKG6P NIfCUGI4OiCq MonaTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=> M3\wb|I{OzF5NES2
WM266 NEDqeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4[pNIOTByIH7N NITl[JA4OiCq NE\kSJhKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNWQhdXW2YX70ZZRqd25? M4DjPVI{OzF5NES2
M257 NV23WHZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojsNVAxKG6P Mn\SO|IhcA>? NX7r[XBoTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG NVLQUHVVOjN|MUe0OFY>
LCP M1XFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TQNFExOCCwTR?= NVPlU4xmPzJiaB?= M4TEZmlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25? NXTIeWk2OjN|MUe0OFY>
WM266 M4XYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv1d4oyODBibl2= NFXnPY04OiCq MkjYTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w NVjWc2k{OjN|MUe0OFY>

... Click to View More Cell Line Experimental Data

In vivo試験 Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]
臨床試験 Dabrafenib is currently in phase 3 clinical trial in patients with melanoma.
特集

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dabrafenib (GSK2118436) SDF
分子量 519.56
化学式

C23H20F3N5O2S2

CAS No. 1195765-45-7
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 30 mg/mL (57.74 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 8 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

カスタマーフィードバック (4)


Click to enlarge
Rating
Source J Clin Invest, 2014, 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck
Method Western blot
Cell Lines A375P cells
Concentrations 10 uM
Incubation Time 48 h
Results GSK2118436 inhibition produced an additive increase in LC3II/LC3I ratio, but the combination of GSK2118436 with HCQ produced substantial increases in LC3II/LC3I ratio and p62 levels, and the triple drug combination (GSK2118436, GSK1120212, and HCQ) produced the most substantial increase in LC3II/LC3I ratio and buildup of p62, indicative of simultaneous autophagy induction and distal autophagy blockade.

Click to enlarge
Rating
Source J Clin Invest, 2014, 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck
Method Western blot
Cell Lines CLL cells
Concentrations 6 uM
Incubation Time 24 h
Results Levels of phosphorylated ERK (pERK) and total ERK (tERK) in enriched CD19+CD5+ CLL cells or CD14+ monocytes were measured by Western blot analysis. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle(Left). The quantitative results had shown in right(P < 0.01).

Click to enlarge
Rating
Source Transl Res, 2014, 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck
Method MTT assay
Cell Lines FRO and SW1736 cells
Concentrations 0-5 uM
Incubation Time 72 h
Results Dabrafenib showed inhibition of cell growth with concentrations between 0.5 and 5 uM.

Click to enlarge
Rating
Source Cell Death Dis, 2014, 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck
Method TUNEL staining
Cell Lines C57Bl/6J mice
Concentrations 100/300 mg/kg
Incubation Time 1 h
Results Dabrafenib protects mice from acetaminophen-induced hepatotoxicity.The pretreatment of mice with dabrafenib (100 mg/kg or 300 mg/kg) apparently eased the acetaminophen-caused liver injury.

文献中の引用 (10)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Raf 阻害剤

  • LY3009120

    LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204)新しくて強力な阻害剤で、 B-RAFV600Eに作用すると、IC50 が 31 nMになる。

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Sorafenib

    Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylateは、Raf-1、B-RafとVEGFR-2のマルチキナーゼ阻害剤で、IC50 がそれぞれ 6 nM、 22 nM、90 nMです。

  • PLX-4720

    PLX-4720は、B-Raf(V600E)とc-Raf-1(Y340D/Y341D)の「実行中の」形の強力で選択的な阻害剤で、IC50 がそれぞれ 13 nM と 6.7 nMです。

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

最近チェックしたアイテム

Tags: Dabrafenib (GSK2118436)を買う | Dabrafenib (GSK2118436)供給者 | Dabrafenib (GSK2118436)を購入する | Dabrafenib (GSK2118436)費用 | Dabrafenib (GSK2118436)生産者 | オーダーDabrafenib (GSK2118436) | Dabrafenib (GSK2118436)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ